Moreover, the inhibition of thrombopoietin and IL-6 expression abrogated thrombocytosis in tumor-bearing mice and significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer [24]. This evidence concerns the gene THPO and Thrombocytosis.